pembrolizumab
merck
['nsclc', 'sclc', 'pembro']
adjuvant pembrolizumab significantly improved dps vs placebo in completely resected, stage ib iiia nsclc, regardless of pd-l1 (unexpected outperformance of placebo in pdl1 high patients). #esmo22 simultaneous publication in 
MD, PhD, Prof of Respiratory Medicine, Thoracic Oncology Specialist @CHUdeToulouse, @IUCTOncopoleICR; Researcher, INSERM @crctoncopole #LCSM ????? ?? ??